Gilead Sciences broke ground on its new $180,000-square-foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City headquarters, aiming to accelerate biologics discovery and manufacturing innovation. The facility will incorporate flexible labs and advanced digital infrastructure, including autonomous robotics and real-time monitoring, to support next-generation therapies. This investment complements Gilead’s recent FDA commitment to distribute Yeztugo as part of the PEPFAR program, expanding access to antiviral treatments globally.